CWF19L1 is a spliceosomal protein that functions as a regulator of mRNA splicing and alternative splicing events 1. The protein interacts with key splicing factors including U5 small nuclear ribonucleoprotein components and the PRPF19 complex within the nucleus 1, facilitating post-mRNA release spliceosomal complex functions and RNA lariat debranching enzyme activity. Beyond its splicing roles, CWF19L1 influences metabolic pathways: genetic variants in the CWF19L1 locus are associated with visceral adipose tissue accumulation and type 2 diabetes susceptibility 2, and the gene cluster containing CWF19L1 influences both hepatic fat deposition and inflammation in nonalcoholic fatty liver disease 3. CWF19L1 also promotes T-cell-mediated cytotoxicity by regulating alternative splicing of immune-related genes and upregulating effector cytokines 1. Clinically, biallelic pathogenic variants in CWF19L1 cause spinocerebellar ataxia, autosomal recessive 17 (SCARRAX17), presenting with developmental delay, progressive cerebellar ataxia, cerebellar atrophy, and treatment-resistant epilepsy 456. The phenotypic spectrum ranges from early-onset childhood developmental encephalopathy to late-onset adult-presenting ataxia 54, suggesting widespread neurological consequences of CWF19L1 dysfunction beyond pure cerebellar involvement.